Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol) ...
Zacks.com on MSN1d
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in FocusExelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...
Overdiagnosis of thyroid cancer in the United States remains a persistent problem, according to a study published online Feb.
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...
Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.
The following is a summary of “Mediating role of thyroid-related hormones between thyroid dysfunction diseases and osteoporosis: a mediation mendelian randomization study,” published in the February ...
COVID-19 vaccination is linked to a transient decrease in hyperthyroidism risk but an increase in hypothyroidism risk over 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback